EVH vs. RCM, PINC, FC, IT, EPAM, TOST, FFIV, ALAB, OLED, and TWLO
Should you be buying Evolent Health stock or one of its competitors? The main competitors of Evolent Health include R1 RCM (RCM), Premier (PINC), Franklin Covey (FC), Gartner (IT), EPAM Systems (EPAM), Toast (TOST), F5 (FFIV), Astera Labs (ALAB), Universal Display (OLED), and Twilio (TWLO).
Evolent Health (NYSE:EVH) and R1 RCM (NASDAQ:RCM) are both mid-cap computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.
Evolent Health received 261 more outperform votes than R1 RCM when rated by MarketBeat users. Likewise, 73.88% of users gave Evolent Health an outperform vote while only 58.02% of users gave R1 RCM an outperform vote.
In the previous week, R1 RCM had 4 more articles in the media than Evolent Health. MarketBeat recorded 8 mentions for R1 RCM and 4 mentions for Evolent Health. R1 RCM's average media sentiment score of 1.36 beat Evolent Health's score of 1.34 indicating that R1 RCM is being referred to more favorably in the news media.
61.1% of R1 RCM shares are owned by institutional investors. 1.6% of Evolent Health shares are owned by company insiders. Comparatively, 36.8% of R1 RCM shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Evolent Health presently has a consensus target price of $42.00, indicating a potential upside of 93.55%. R1 RCM has a consensus target price of $15.83, indicating a potential upside of 27.38%. Given Evolent Health's stronger consensus rating and higher possible upside, equities analysts clearly believe Evolent Health is more favorable than R1 RCM.
R1 RCM has a net margin of -1.39% compared to Evolent Health's net margin of -5.07%. Evolent Health's return on equity of 6.90% beat R1 RCM's return on equity.
Evolent Health has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, R1 RCM has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
R1 RCM has higher revenue and earnings than Evolent Health. R1 RCM is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.
Summary
Evolent Health and R1 RCM tied by winning 9 of the 18 factors compared between the two stocks.
Get Evolent Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evolent Health Competitors List
Related Companies and Tools
